No abstract available.
Humans ; Striae Distensae* ; Vitiligo*

OBJECTIVETo discuss the Chinese version of reflux symptom index (RSI) scale's reliability, validity and clinical value.

METHODSUsing the Chinese version of RSI scale on the ENT outpatients. There are one hundred and seven patients, included thirty-five patients with common throat (non-suspected) and seventy-two patients with clinically suspected throat reflux. 107 patients are to complete the two scales before and after one week. Thirteen patients with common throat(non-suspected) diseases and forty-one with suspected throat reflux also received RSI testing. Among the thirty-four confirmed acid reflux disease patients, thirty patients received pharmaceutical treatments and self-performed post-RSI testing after three months.

RESULTSThe RSI Scale internal reliability consistency included the test-retest reliability (0.750 - 0.971), discriminant validity and construct validity. RSI total targeting percentage of 66.7%, targeting percentage is 80.8%, discriminant validity using 2 independent samples Wilcoxon test, RSI total score compared to Z = -3.266, P = 0.001. The before and after treatment self-control chi-square test (P < 0.05), difference was statistically significant.

CONCLUSIONSRSI Simplified Chinese version has good reliability and validity, and can be used for laryngopharyngeal reflux disease (LPRD) diagnostic screening along with the efficacy for the treatment of patients with appropriate LPRD aids.

Adolescent ; Adult ; Aged ; Aged, 80 and over ; Female ; Gastroesophageal Reflux ; diagnosis ; Humans ; Laryngopharyngeal Reflux ; diagnosis ; Male ; Middle Aged ; Reference Standards ; Severity of Illness Index ; Surveys and Questionnaires ; Young Adult

ATP Binding Cassette Transporter, Sub-Family G, Member 2 ; ATP-Binding Cassette Transporters ; antagonists & inhibitors ; genetics ; Adenoviridae ; genetics ; Breast Neoplasms ; therapy ; Cell Line, Tumor ; Drug Resistance, Multiple ; Drug Resistance, Neoplasm ; Gene Silencing ; Humans ; Mitoxantrone ; pharmacokinetics ; Neoplasm Proteins ; antagonists & inhibitors ; genetics ; RNA Interference ; RNA, Small Interfering ; pharmacology

OBJECTIVETo establish an easily reproducible animal model of hypospadias and to test whether Atrazine can induce hypospadias in animal experiment.

METHODSFrom the 11th to 16th day after conception, 120 conceived SD rats were divided randomly into 6 groups: one coin oil group (1 ml/kg/d), two finasteride groups (10 mg/kg/d, 20 mg/kg/d), three Atrazine groups (25 mg/kg/d, 100 mg/kg/d, 200 mg/kg/d). When all pregnant rats had delivered, the new born rats were counted and the penis appearance, urethral orifice position and micturition were observed with magnifying lens and anatomy microscope.

RESULTSHypospadias were found in new born male rats treated prenatally with Finasteride (10 mg/kg/d, 20 mg/kg/d) and 200 mg/kg/d Atrazine groups. The incidence was 28.30%, 67.03%, 10.23% respectively. Embryotoxic effects were observed at 25 mg/kg/d Atrazine group in 2 rats and associated with no severe maternal toxicity.

CONCLUSIONS(1) A hypospadias SD rats model can be established by Finasteride and it is easily reproducible. (2) The Atrazine was teratogenic to the SD rats, embryotoxic effects were observed at the low dose level and associated with no severe maternal toxicity.

Animals ; Atrazine ; adverse effects ; Disease Models, Animal ; Female ; Finasteride ; adverse effects ; Hypospadias ; chemically induced ; Male ; Pregnancy ; Rats ; Rats, Sprague-Dawley ; Teratogens

OBJECTIVETo screen gene mutation in alpha-galactosidase A (alpha-Gal A) in a nonconsanguineous Chinese family with Fabry disease (FD) with clinical manifestations similar to hypertrophic cardiomyopathy (HCM).

METHODSMutation analysis was performed by using purified PCR products to direct sequence analysis on an ABI-377XL automated DNA sequencer. DNA analysis of alpha-Gal A gene and physical and clinical examinations were performed in a female proband and in her relatives (15 subjects in total).

RESULTSThree hemizygotes and 6 heterozygotes were diagnosed for FD by the alpha-Gal A gene analysis with a missense mutation in exon 5 of the alpha-Gal A sequence, leading to a TGG32TGA substitution, which may induce the absent of tryptophan's translation (corresponded to TGG) by the terminator codon TGA. Six patients in the family were revealed as HCM by echocardiography.

CONCLUSIONSPresent results show that it is important to differentiate FD from other causes of hypertrophy in patients with cardiac hypertrophy. Screening for alpha-Gal A gene mutations in patients with FD and in their relatives could help to identify all suspected cases within the families.

Adolescent ; Adult ; Cardiomyopathy, Hypertrophic ; diagnosis ; Child ; DNA Mutational Analysis ; Fabry Disease ; diagnosis ; genetics ; Female ; Humans ; Male ; Middle Aged ; Mutation ; Pedigree ; alpha-Galactosidase ; genetics

Aim To explore the mechanism of action of the active ingredients of Callerya nitida var.hirsutissima corresponding to the target gene in the treatment of triple-negative breast cancer(TNBC), using network pharmacology, molecular docking technology and in vitro experimental verification.Methods Based on literature research and combined with database screening, the main active components of Callerya nitida var.hirsutissima and the related targets of TNBC were obtained.Intersection genes were found to construct a protein interaction(PPI)network diagram, and core targets were screened according to the size of the correlation.A core target interaction network model of "Traditional Chinese Medicine-Ingredients-Targets-Disease" was constructed.The intersection targets were analyzed for gene GO function and KEGG pathway enrichment analysis.Finally, molecular docking and in vitro experimental verification of the selected components and the target were carried out.Results A total of 38 active components of Callerya nitida var.hirsutissima were collected, as well as 388 related potential targets, 3 919 TNBC targets, and 277 Callerya nitida var.hirsutissima therapeutic targets for TNBC.It mainly acted on multiple targets such as PIK3R1, PIK3CA, MAPK1, AKT1, SRC, etc.In in vitro experiments, it could be seen that the chloroform fraction of Callerya nitida var.hirsutissima and the monomer compounds luteolin and betulin had certain inhibitory effects on cell proliferation.All groups could inhibit the expression of VEGFA, AKT, PIK3CA, CDK1, CDK4 within the range of administration concentration.Conclusions Based on network pharmacology and molecular docking methods, this study explores the possible targets and signaling pathways of Callerya nitida var.hirsutissima in the treatment of TNBC, and conducts in vitro verification experiments to further verify the prediction of network pharmacology.